Skip to content
Sign in

Business opportunities

Who each startup should sell to, sell through, build with, enter a market with or raise from, read from the whole network. Every opportunity comes with its reasoning, the evidence and a first step.

SWC 2026 Finalist

Defined Bioscience

San Diego maker of fully defined, serum-free stem cell media that lower cost and variability for iPSC research and biomanufacturing.

Open the dossier
Opportunities
3
High confidence
070% and above
Counterparts
3startups and investors
  • Customers 1
  • Co-development 1
  • Investors 1

Customers1

Who could buy, or sell through

Design-in before StemSight's clinical process is locked

StemSight is developing iPSC-derived corneal cells with clinical trials targeted around 2027; media choice now will be locked into its regulated process. A collaboration to qualify Defined Bioscience media for its differentiation protocol could create a long-term clinical customer and generate comparative data.

35%confidence

Evidence from the records

  • “Fully defined media formulations with stabilized growth factors, reducing the cost and variability of stem cell culture.”
  • “Corneal cells derived from induced pluripotent stem cells (iPS); clinical trials targeted around 2027.”
If it works
A clinical-stage reference customer and recurring media volume through trials.
First step
Offer StemSight free evaluation kits of HiDef-B8 with a joint comparison protocol.

Co-development1

An integration or joint product

Stem cell culture in microgravity research programmes

G-Space helps biotech companies identify where microgravity offers a commercial advantage and works with Redwire, Voyager and tissue-chip projects. Defined, low-variability media are valuable for space experiments where every run is expensive; a joint offering could put Defined Bioscience into microgravity biomanufacturing studies.

15%confidence

Evidence from the records

  • “Range of 11 media and reagents on sale”
  • “helps biotech and materials companies identify where microgravity offers a commercial advantage and scale up”
  • “NASA SBIR Phase I grant (tissue chips)”
If it works
A niche but high-visibility application and introductions to space-biotech customers.
First step
Ask G-Space which of its clients run stem cell experiments and propose a joint application note.

Investors1

A fund whose thesis fits

Seed round from a science-focused US biotech investor

Defined Bioscience has only an NIH SBIR grant and needs capital for GMP products and sales. KdT invests in US biotech and deep tech from pre-seed to Series A with $0.5–5M tickets and backed ZymoChem in the network.

30%confidence

Evidence from the records

  • “$1.5M (NIH SBIR Phase II grant); no public equity round found”
  • “Biotech & life sciences”
  • “GS Futures, KdT Ventures, Cavallo Ventures (existing investors before the Series A)”
If it works
A first equity round financing GMP development and a commercial team.
First step
Ask ZymoChem's CEO for an introduction to KdT Ventures.

Analyst reading of 21 Nov 2026, from the public record of the network. Method: analyst-ai.

Most promising across the network

587 opportunities analysed
  1. Critical Medical DeviceswithLove LifesciencesPeers

    Share drug-delivery device lessons with Love Lifesciences

    Both are US pre-seed drug-delivery device companies founded around a clinical pain point. Exchanging contract manufacturer, regulatory consultant and pharma-partnering contacts saves both time and money.

    30%
  2. Roam TechnologieswithByonyksPeers

    Learn from Byonyks' 2025 FDA class II clearance and US launch set-up

    Byonyks obtained FDA 510(k) clearance for a home-therapy device and is setting up US infrastructure, the exact path Roam must follow. A founder exchange can shorten Roam's regulatory and DME launch planning.

    30%
  3. Lampsy HealthwithLegit.HealthPeers

    Learn from Legit.Health's medical-device certification path

    Legit.Health took an AI medical device through CE marking with an ISO 13485 quality system in Iberia; Lampsy faces the same regulatory steps. A founder exchange shortens the learning curve.

    30%
  4. AlgatekwithAtoz Carbon Cycle PlatformPeers

    Regional microalgae alliance for Malaysia

    Atoz builds nature-based carbon solutions with microalgae in Malaysia but has no public traction; Algatek has installed units at Indonesian SOEs. Sharing technology, MRV methods and possibly licensing Algatek units into Malaysia would give both a bigger regional story.

    25%
  5. Atoz Carbon Cycle PlatformwithAlgatekPeers

    Learn from a deployed microalgae business next door

    Algatek has leased microalgae units to Indonesian SOEs and claims IoT-monitored capture; Atoz has a prototype. Licensing or co-selling Algatek's MicroForest in Malaysia could give Atoz an immediate product while it builds its platform.

    25%
  6. Love LifescienceswithCritical Medical DevicesPeers

    Share FDA and QMS learnings between two pre-clearance drug-delivery devices

    Both companies are pre-FDA drug-delivery device makers founded by clinicians. Sharing regulatory consultants, QMS templates and test labs reduces cost for both.

    25%
  7. ZymoChemwithYeast Bay BioPeers

    Davis fermentation network and scale-up playbook

    ZymoChem's CEO trained at UC Davis, where Yeast Bay Bio was founded in 2025. Sharing contract-fermentation contacts, scale-up lessons and DOE/grant experience is low cost and high value for a seed-stage fermentation company.

    25%
  8. LainTechwithBaniqlPeers

    Battery-metals alliance between two atmospheric leaching processes

    Baniql produces battery-grade nickel MHP from Indonesian laterites at low temperature and pressure; Lain Tech treats sulfides containing cobalt and nickel. Together they can present battery offtakers a complementary low-carbon hydrometallurgy portfolio and share know-how on catalysts and scale-up.

    25%
  9. Amass BiosystemswithRegenratePeers

    Borrow Regenrate’s contract-farming model for intercrops

    Regenrate monetises the intercrop period in France with free seed and guaranteed purchase prices — the same farmer-economics problem Amass must solve. Its contract design is a template for Amass' farmer offer.

    20%
  10. BILIXwithPleryon TherapeuticsPeers

    Exchange on polymer-drug CMC and Asian licensing

    Both companies develop polymer-based therapeutics at Series A in Asia. Sharing CMC suppliers, regulatory strategy and licensing contacts reduces cost and time for both.

    20%
  11. Pleryon TherapeuticswithBioSapienPeers

    Compare local-delivery regulatory playbooks

    Both companies build localised, extended-release delivery platforms (BioSapien in oncology implants, Pleryon in ophthalmology). Sharing regulatory and CMC learnings on biodegradable delivery systems reduces costly missteps.

    20%
  12. RegenratewithAmass BiosystemsPeers

    Exchange intercrop-for-bioenergy playbooks

    Amass grows a bioenergy crop alongside corn for biomass; Regenrate grows camelina between crops for biofuel. Both sell farmer income diversification to energy buyers and can share off-take and agronomy learnings across EU/US.

    20%
  13. FluvwithTausiPeers

    Share the gig-provider OS playbook

    Tausi runs an AI-powered operating system for independent beauticians with verified providers and a commission model. Fluv faces the same supply-side problem with pet-sitters; exchanging verification, training and retention practices is useful for both.

    15%
  14. PromptendwithNeurath AIPeers

    AI reliability peer exchange

    Both address trust in AI outputs (Promptend for generated code, Neurath for model predictions) and sell to risk-averse engineering buyers; sharing go-to-market learnings on assurance products is useful.

    15%
  15. PsychoTechwithPromptendPeers

    Moldovan finalist cohort coordination

    Both represent Moldova at the SWC final; pooling travel, investor meetings and Startup Moldova support reduces cost, and PsychoTech could pilot Promptend on its client code.

    15%
  16. ShopperoowithPardon AIPeers

    Benchmark against Pardon AI's profitability agents

    Pardon AI sells AI agents that optimise revenue and margins for retail and food service and has been through Techstars. A founder exchange clarifies positioning and possible specialisation (pricing/assortment vs broader profitability).

    15%
  17. VIEROC AIwithWiseUnitPeers

    Exchange voice-agent and chat-agent learnings with WiseUnit

    WiseUnit sells an AI phone receptionist; VIEROC focuses on chat agents. Comparing pricing, churn and model costs, or white-labelling each other's channel, could help both small teams.

    15%
  18. SchoolACEwithKetzaiPeers

    Learn from Ketzai’s path to 40,000 teachers

    Ketzai solved teacher acquisition for AI lesson planning by aligning with official curricula; SchoolACE can learn its playbook and potentially share content tooling for Spanish-speaking US classrooms.

    15%

Similar profiles

Compatibility score with Defined Bioscience

Scored on needs and offers, market bridge, customer potential, sector synergy and stage. Open a profile to see each dimension.